Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
5.00
-0.01 (-0.20%)
At close: Jul 16, 2026, 4:00 PM EDT
4.883
-0.120 (-2.34%)
Pre-market: Jul 17, 2026, 8:01 AM EDT
Agenus Employees
Agenus had 81 employees as of December 31, 2025. The number of employees decreased by 235 or -74.37% compared to the previous year.
Employees
81
Change (1Y)
-235
Growth (1Y)
-74.37%
Revenue / Employee
$1,529,210
Profits / Employee
$794,951
Market Cap
208.21M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 81 | -235 | -74.37% |
| Dec 31, 2024 | 316 | -73 | -18.77% |
| Dec 31, 2023 | 389 | -144 | -27.02% |
| Dec 31, 2022 | 533 | 92 | 20.86% |
| Dec 31, 2021 | 441 | 82 | 22.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Karyopharm Therapeutics | 228 |
| Nautilus Biotechnology | 127 |
| Immunic | 95 |
| Keros Therapeutics | 87 |
| Precision BioSciences | 66 |
| Camp4 Therapeutics | 48 |
| NovaBridge Biosciences | 30 |
AGEN News
- 3 days ago - Why Is Agenus (AGEN) Stock Up Today? - TipRanks
- 3 days ago - Agenus price target raised to $30 from $23 at H.C. Wainwright - TheFly
- 3 days ago - Agenus announces strategic prioritization of neoadjuvant BOT+BAL - TheFly
- 3 days ago - Agenus Transcript: Investor update - Transcripts
- 3 days ago - Agenus Press release: Investor update - Filings
- 3 days ago - Agenus Slides: Investor update - Filings
- 4 days ago - Agenus announces $340M private placement - TheFly
- 4 days ago - Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer - Business Wire